Онкология 188RE-ZOLEDRONIC ACID IS A NEW RUSSIAN ADIOPHARMACEUTICAL TO TREAT BONE METASTASES: THE FIRST CLINICAL EXPERIENCE
eng
ONCOLOGY BULLETIN OF THE VOLGA REGION

Scientific-practical Journal for general practitioners and researchers

Search

188RE-ZOLEDRONIC ACID IS A NEW RUSSIAN ADIOPHARMACEUTICAL TO TREAT BONE METASTASES: THE FIRST CLINICAL EXPERIENCE

T.Yu. Kochetova1, V.V. Krylov1, M.Y. Smolyarchuk1, L.V. Voloznev2, A.S. Lunev3
1 Federal State Institution «Medical Radiological Research Center» of the Ministry of Health of the Russian Federation, Obninsk
2 Skryabin Moscow State Academy of Veterinary Medicine and Biotehnology, Moscow
3 Burnasyan Federal Medical Biophysical Centre, Moscow

 

Kochetova T.Yu. — researcher of the Department of radiosurgical treatment of open radionuclides 4 Korolev St., Obninsk, Russian Federation, 249036, tel.: (48439) 9-33-85, +7-919-034-58-38, e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра.

 

Abstract. 188Re-zoledronic acid is new Russian radiopharmaceutical to treat patients with multiple painful bone metastases. The main aim of this study was to determine the maximum tolerated dose of 188Re-zoledronic acid. Ten patients in three groups received a single injection of escalating doses of the pharmaceutical (35, 45 and 55 MBq/kg). Blood counts and biochemical parameters were measured weekly over a period of 8 weeks. There wasn’t any difference in hematologic toxicity between the groups. On the 4th-5th weak after injection a temporary decrease (from 2 to 40%, 16% on average) of platelets count was found, maximal rate of decrease was in the first group (injected activity 35 MBq/kg). There was no evidence of hematological toxicity grade II-IV. Two patients from the third group (55 MBq/kg) showed reversible hepatic toxicity grade I and II (transaminase level increase). In nine of ten cases, analgesic lasting effect was succeeded. 188Re-zoledronic acid is potentially effective and safe radiopharmaceutical to treat painful bone metastases in dosage of 55 MBq/kg.

Key words: radinuclide therapy, bone metastases, palliative therapy, pain syndrome, radiopharmaceutical, zoledronic acid.





Наши партнеры



Copyright © 2014 | Все права защищены
RAFANDOS.COM | SUPPORT